Oral Semaglutide Tops Sitagliptin for Cutting HbA1c, Weight in T2D
(MedPage Today) -- Positive results from PIONEER 3 trial in diabetic patients who aren ' t responding to metformin with or without sulfonylurea (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 24, 2019 Category: Cardiology Source Type: news
Metformin vs. Januvia
Title: Metformin vs. JanuviaCategory: MedicationsCreated: 12/20/2018 12:00:00 AMLast Editorial Review: 12/20/2018 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 20, 2018 Category: Endocrinology Source Type: news
Steglujan (Ertugliflozin and Sitagliptin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 9, 2018 Category: Drugs & Pharmacology Source Type: news
Type 2 Diabetes Drugs Linked to Bullous Pemphigoid Type 2 Diabetes Drugs Linked to Bullous Pemphigoid
Small increased risk of blistering skin disease seen with some DPP-4 inhibitors, such as vildagliptin and linagliptin, but not others, such as sitagliptin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Sitagliptin-Metformin Therapy in Prior Gestational Diabetics Sitagliptin-Metformin Therapy in Prior Gestational Diabetics
Find out about the benefits treatment with sitagliptin combined with metformin may provide prediabetic women with a history of gestational diabetes.Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Novo's pioneering diabetes pill beats Victoza, Januvia in tests
COPENHAGEN (Reuters) - Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck& Co's Januvia and its own best-selling injectable treatment Victoza in tests. (Source: Reuters: Health)
Source: Reuters: Health - June 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Liraglutide cost saving versus sitagliptin for T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news
Class of type 2 diabetes drugs doesn't cut death risk compared to placebo
Comparing three classes of type 2 diabetes drugs, researchers found one class, which includes Onglyza and Januvia, did not reduce death risk. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 18, 2018 Category: Consumer Health News Source Type: news
Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk
How to find good candidates?
Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed.
To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news
Steglujan (Ertugliflozin and Sitagliptin Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 28, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes
KENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2017 Category: Drugs & Pharmacology Source Type: news
Targeting a microRNA shows potential to enhance effectiveness of diabetes drugs
(University of Alabama at Birmingham) Researchers have found a vital role for miR-204 in beta cells -- regulating the cell surface receptor that is the target of many of the newer type 2 diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta. This drug target is the glucagon-like peptide 1 receptor, or GLP1R. Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news
Ertugliflozin: Promise From Yet Another SGLT-2 Inhibitor (CME/CE)
(MedPage Today) -- Assessed as triple agent therapy when added to metformin, sitagliptin (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 25, 2017 Category: Cardiology Source Type: news
Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials
In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). (Source: World Pharma News)
Source: World Pharma News - September 12, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
